Skip to content
The Policy VaultThe Policy Vault

Ultomiris subcutaneousMedica

Atypical hemolytic uremic syndrome (aHUS)

Initial criteria

  • Patient age ≥ 18 years
  • Patient does not have Shiga toxin E. coli-related hemolytic uremic syndrome
  • Patient has received or will receive Ultomiris intravenous infusion loading dose prior to initiation of Ultomiris subcutaneous
  • Medication is prescribed by or in consultation with a nephrologist

Approval duration

1 year